AstraZeneca to acquire US-based Alexion for $39 billion
Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said
- Dec 12, 2020,
- Updated Dec 12, 2020 8:06 PM IST
Astrazeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.
Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said.
Also read: Sputnik V to AstraZeneca: 'Combine your vaccine with ours to boost efficacy'
Also read: AstraZeneca to test combining coronavirus vaccine with Sputnik V shot
Astrazeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.
Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said.
Also read: Sputnik V to AstraZeneca: 'Combine your vaccine with ours to boost efficacy'
Also read: AstraZeneca to test combining coronavirus vaccine with Sputnik V shot